Intradigm closes $21.4M for cancer therapeutics
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
The Palo Alto, Calif.-based company says it… Continue Reading
Intradigm lands $18.5M to advance oncology treatment
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, and existing investors Alta Partners, Frazier Healthcare Ventures,… Continue Reading
Life-science briefing: Thursday, April 10, 2008
TODAY’S HEADLINES:
HealthExtras buys venture-backed PBM HospiScript for $100M (release)
Urological device-maker NeoTract adds $7.4M (VentureWire)
RNAi-drug startup Intradigm seeks $35M (VentureWire)
Israel’s Arbel Medical raises $3.5M for tumor cryotherapy (release)
HealthExtras buys venture-backed PBM HospiScript for $100M — HospiScript Services, a Montgomery, Ala., prescription-benefits manager, agreed to be acquired… Continue Reading
Intradigm, a gene targeting co., raises $16M
Intradigm, a Palo Alto biotech company that is using a technology called “RNA interference” (RNAi) to target genes while providing oncology medical treatments, has raised $16 million in a first round of funding.
It has also moved to Palo Alto, from Rockville, Maryland, driven by the… Continue Reading